Skip to content
AIRS

Airsculpt Technologies, Inc.

Airsculpt Technologies, Inc. Q4 FY2024 earnings call

March 14, 2025 · fiscal period ended 2024-12

EPS · actual vs est

$-0.08 / $0.02Miss -500.0%

Revenue · actual vs est

$39.2M / $49.6MMiss -21.0%
Ask about this call

Summary

Generated 2025-03-14

Management highlights

  • Yogesh highlighted the company's challenges in 2024 but emphasized confidence in the strategy to enhance culture and improve go-to-market strategy. Key priorities include marketing (focusing on returns-based approach and testing new channels), sales (strengthening consultative model), new services (exploring individual services and new ones like skin tightening pilot), customer experience (evaluating and improving journey), and technology (introducing solutions to aid sales and patient care). - Dennis reviewed financial results, noting revenue decline due to lower case and lead volume, cost of services change, SG&A expenses decline, and balance sheet details including cash, debt, and cash flow from operations. He also mentioned pausing de novo openings to focus on existing centers.
View in transcript ↓

Segment performance

For the fourth quarter of 2024, revenue totaled $39.2 million, declining 17.7% from Q4 2023 with case volume down 16.7%. Same-store revenue declined 22.6%. Adjusted EBITDA was $1.9 million, or 4.7% of revenue. For the full year 2024, revenues were $180.4 million, a 7.9% decline from fiscal 2023, and adjusted EBITDA totaled $20.7 million with an adjusted EBITDA margin of 11.5%.

View in transcript ↓

Guidance

  • Not providing full fiscal year 2025 guidance yet, expecting to introduce it when reporting first quarter results in May. - Expect first quarter 2025 same-store revenue decline similar to Q4 2024. - Pausing de novo center openings to focus on revenue growth in existing centers. - Expecting compliance with credit agreement terms throughout fiscal year.
View in transcript ↓

Risks

  • Challenging consumer spending environment impacting sales. - Impact of marketing spend reductions on lead volumes. - Macro environment pressures affecting business performance.
View in transcript ↓

Q&A highlights

Q: Could you give more color on sequential growth each quarter and EBITDA expectations?

A: Yogesh mentioned expecting similar seasonal trends with sequential improvement, with Q2 likely higher than Q1 and 3Q higher than 2Q. Dennis added on the revolver drawdown and de novo centers' performance.

Q: Can you speak to liquidity improvement actions and cost savings program?

A: Dennis explained revolver drawdown for marketing support, and Yogesh discussed cost savings from corporate headcount adjustments, with $3 million annual savings, most executed and benefits starting in Q1.

Q: Details on new marketing efforts like online video and skin tightening pilot?

A: Yogesh said marketing includes returns-based approach, testing online video and social channels, and skin tightening pilot as a stand-alone service to capitalize on consumer trends

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS$-0.08$0.02-500.0%$0.01
Revenue$39.2M$49.6M-21.0%$47.6M

Transcript

March 14, 2025

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.